Indivior Pharmaceuticals, Inc. Increase (Decrease) in Other Operating Liabilities
Indivior Pharmaceuticals, Inc. (SUPN) reported Increase (Decrease) in Other Operating Liabilities of -$13.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingLiabilities · last filed 2026-08-03
- Indivior Pharmaceuticals, Inc. increase (decrease) in other operating liabilities for the quarter ending 2026-06-30 was $73.00M, a 46.00% increase year-over-year.
- Indivior Pharmaceuticals, Inc. increase (decrease) in other operating liabilities for the quarter ending 2026-03-31 was -$86.00M, a 206.17% decline year-over-year.
- Indivior Pharmaceuticals, Inc. increase (decrease) in other operating liabilities for the quarter ending 2025-12-31 was -$8.00M.
- Indivior Pharmaceuticals, Inc. increase (decrease) in other operating liabilities for the quarter ending 2025-09-30 was -$82.00M, a 920.00% decline year-over-year.
- Indivior Pharmaceuticals, Inc. increase (decrease) in other operating liabilities for fiscal 2025 was $41.00M, a 412.50% increase from fiscal 2024.
- Indivior Pharmaceuticals, Inc. increase (decrease) in other operating liabilities for fiscal 2024 was $8.00M, a 92.73% decline from fiscal 2023.
- Indivior Pharmaceuticals, Inc. increase (decrease) in other operating liabilities for fiscal 2023 was $110.00M.
| Period end | Increase (Decrease) in Other Operating Liabilities 3 month | Increase (Decrease) in Other Operating Liabilities 6 month | Increase (Decrease) in Other Operating Liabilities 9 month | Increase (Decrease) in Other Operating Liabilities 12 month | Increase (Decrease) in Other Operating Liabilities 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $73.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | -$13.00M 10-Q · filed 2026-08-03 | -$21.00M derived: sum of 3 quarters · filed 2026-08-03 | -$103.00M derived: sum of 4 quarters · filed 2026-08-03 | |
| 2026-03-31 | -$86.00M 10-Q · filed 2026-04-30 | -$94.00M derived: sum of 2 quarters · filed 2026-04-30 | -$176.00M derived: sum of 3 quarters · filed 2026-04-30 | -$126.00M derived: sum of 4 quarters · filed 2026-08-03 | |
| 2025-12-31 | -$8.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$90.00M derived: sum of 2 quarters · filed 2026-02-26 | -$40.00M derived: sum of 3 quarters · filed 2026-08-03 | $41.00M 10-K · filed 2026-02-26 | |
| 2025-09-30 | -$82.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | -$32.00M derived: sum of 2 quarters · filed 2026-08-03 | $49.00M 10-Q · filed 2025-10-30 | -$14.00M derived: sum of 4 quarters · filed 2026-08-03 | |
| 2025-06-30 | $50.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $131.00M 10-Q · filed 2026-08-03 | $68.00M derived: sum of 3 quarters · filed 2026-08-03 | $78.00M derived: sum of 4 quarters · filed 2026-08-03 | |
| 2025-03-31 | $81.00M 10-Q · filed 2026-04-30 | $18.00M derived: sum of 2 quarters · filed 2026-04-30 | $28.00M derived: sum of 3 quarters · filed 2026-04-30 | $89.00M derived: sum of 4 quarters · filed 2026-04-30 | |
| 2024-12-31 | -$63.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$53.00M derived: sum of 2 quarters · filed 2026-02-26 | $8.00M derived: sum of 3 quarters · filed 2026-02-26 | $8.00M 10-K · filed 2026-02-26 | $14.00M 10-K · filed 2025-03-03 |
| 2024-09-30 | $10.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $71.00M derived: sum of 2 quarters · filed 2025-10-30 | $71.00M 10-Q · filed 2025-10-30 | ||
| 2024-06-30 | $61.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $61.00M 10-Q · filed 2025-07-31 | |||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-01 | ||||
| 2023-12-31 | $110.00M 10-K · filed 2026-02-26 | $114.00M 10-K · filed 2025-03-03 | |||
| 2022-12-31 | -$100.00M 10-Q · filed 2025-10-30 | -$97.00M 10-K · filed 2025-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |